Cytochrome P450 4F3 (EC 1.14.14.1) (20-hydroxyeicosatetraenoic acid synthase) (20-HETE synthase) (CYPIVF3) (Cytochrome P450-LTB-omega) (Docosahexaenoic acid omega-hydroxylase CYP4F3) (EC 1.14.14.79) (Leukotriene-B(4) 20-monooxygenase 2) (Leukotriene-B(4) omega-hydroxylase 2) (EC 1.14.14.94)
1_MPQLS 6_ LSSLG 11_ LWPMA 16_ ASPWL 21_ LLLLV 26_ GASWL 31_ LARIL 36_ AWTYT 41_ FYDNC 46_ CRLRC 51_ FPQPP 56_ KRNWF 61_ LGHLG 66_ LIHSS 71_ EEGLL 76_ YTQSL 81_ ACTFG 86_ DMCCW 91_ WVGPW 96_ HAIVR 101_ IFHPT 106_ YIKPV 111_ LFAPA 116_ AIVPK 121_ DKVFY 126_ SFLKP 131_ WLGDG 136_ LLLSA 141_ GEKWS 146_ RHRRM 151_ LTPAF 156_ HFNIL 161_ KPYMK 166_ IFNES 171_ VNIMH 176_ AKWQL 181_ LASEG 186_ SARLD 191_ MFEHI 196_ SLMTL 201_ DSLQK 206_ CVFSF 211_ DSHCQ 216_ EKPSE 221_ YIAAI 226_ LELSA 231_ LVTKR 236_ HQQIL 241_ LYIDF 246_ LYYLT 251_ PDGQR 256_ FRRAC 261_ RLVHD 266_ FTDAV 271_ IQERR 276_ RTLPS 281_ QGVDD 286_ FLQAK 291_ AKSKT 296_ LDFID 301_ VLLLS 306_ KDEDG 311_ KKLSD 316_ EDIRA 321_ EADTF 326_ MFEGH 331_ DTTAS 336_ GLSWV 341_ LYHLA 346_ KHPEY 351_ QERCR 356_ QEVQE 361_ LLKDR 366_ EPKEI 371_ EWDDL 376_ AQLPF 381_ LTMCI 386_ KESLR 391_ LHPPV 396_ PAVSR 401_ CCTQD 406_ IVLPD 411_ GRVIP 416_ KGIIC 421_ LISVF 426_ GTHHN 431_ PAVWP 436_ DPEVY 441_ DPFRF 446_ DPKNI 451_ KERSP 456_ LAFIP 461_ FSAGP 466_ RNCIG 471_ QAFAM 476_ AEMKV 481_ VLGLT 486_ LLRFR 491_ VLPDH 496_ TEPRR 501_ KPELV 506_ LRAEG 511_GLWLR
1: A cytochrome P450 monooxygenase involved in the metabolism of various endogenous substrates, including fatty acids and their oxygenated derivatives (oxylipins) (PubMed:11461919, PubMed:15145985, PubMed:16547005, PubMed:16820285, PubMed:18065749, PubMed:18182499, PubMed:18577768, PubMed:8486631, PubMed:9675028). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (CPR; NADPH-ferrihemoprotein reductase) (PubMed:9675028). May play a role in inactivation of pro-inflammatory and anti-inflammatory oxylipins during the resolution of inflammation (PubMed:11461919, PubMed:15145985, PubMed:15364545, PubMed:16547005, PubMed:16820285, PubMed:18065749, PubMed:18182499, PubMed:18577768, PubMed:8486631, PubMed:9675028)
2: Catalyzes predominantly the oxidation of the terminal carbon (omega-oxidation) of oxylipins in myeloid cells, displaying higher affinity for arachidonate metabolite leukotriene B4 (LTB4) (PubMed:11461919, PubMed:15364545, PubMed:8486631, PubMed:9675028). Inactivates LTB4 via three successive oxidative transformations to 20-hydroxy-LTB4, then to 20-oxo-LTB4 and to 20-carboxy-LTB4 (PubMed:9675028). Has omega-hydroxylase activity toward long-chain fatty acid epoxides with preference for 8,9-epoxy-(5Z,11Z,14Z)-eicosatrienoate (EET) and 9,10-epoxyoctadecanoate (PubMed:15145985). Omega-hydroxylates monohydroxy polyunsaturated fatty acids (PUFAs), including hydroxyeicosatetraenoates (HETEs) and hydroxyeicosapentaenoates (HEPEs), to dihydroxy compounds (PubMed:15364545, PubMed:9675028). Contributes to the degradation of saturated very long-chain fatty acids (VLCFAs) such as docosanoic acid, by catalyzing successive omega-oxidations to the corresponding dicarboxylic acid, thereby initiating chain shortening (PubMed:18182499). Has low hydroxylase activity toward PUFAs (PubMed:11461919, PubMed:18577768)
3: Catalyzes predominantly the oxidation of the terminal carbon (omega-oxidation) of polyunsaturated fatty acids (PUFAs) (PubMed:11461919, PubMed:16820285, PubMed:18577768). Participates in the conversion of arachidonic acid to 20-hydroxyeicosatetraenoic acid (20-HETE), a signaling molecule acting both as vasoconstrictive and natriuretic with overall effect on arterial blood pressure (PubMed:11461919, PubMed:16820285, PubMed:18577768). Has high omega-hydroxylase activity toward other PUFAs, including eicosatrienoic acid (ETA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (PubMed:16820285, PubMed:18577768). Can also catalyze the oxidation of the penultimate carbon (omega-1 oxidation) of PUFAs with lower efficiency (PubMed:18577768). Contributes to the degradation of saturated very long-chain fatty acids (VLCFAs) such as docosanoic acid and hexacosanoic acid, by catalyzing successive omega-oxidations to the corresponding dicarboxylic acids, thereby initiating chain shortening (PubMed:16547005, PubMed:18182499). Omega-hydroxylates long-chain 3-hydroxy fatty acids, likely initiating the oxidative conversion to the corresponding 3-hydroxydicarboxylic fatty acids (PubMed:18065749). Has omega-hydroxylase activity toward long-chain fatty acid epoxides with preference for 8,9-epoxy-(5Z,11Z,14Z)-eicosatrienoate (EET) and 9,10-epoxyoctadecanoate (PubMed:15145985)